Literature DB >> 18996799

Pituitary adenoma: a clinician's perspective.

Mary Lee Vance1.   

Abstract

OBJECTIVE: To review the underlying causes of pituitary lesions, a rational approach to their diagnosis, and therapeutic options.
METHODS: The types of pituitary lesions and their clinical manifestations are reviewed, and treatment strategies and long-term follow-up are discussed.
RESULTS: A pituitary adenoma is quite common and poses a challenge to the clinician to determine the clinical significance, the appropriate diagnosis, the need for treatment, and the appropriate therapy or therapies. The treatment of a pituitary adenoma depends on the type of tumor; a prolactinoma is treated medically with a dopamine agonist drug, and other lesions are usually treated by transsphenoidal surgical removal. Replacement of a deficient hormone or hormones is necessary for optimal functioning. Some patients require more than one treatment, including surgical intervention, replacement of a hormone or hormones, medications to lower hormone hypersecretion to normal (for prolactinoma, acromegaly, or Cushing disease), pituitary radiation therapy (optimally with focused irradiation such as the Gamma Knife or LINEAC), and, in the situation of persistent Cushing disease, bilateral adrenalectomy as a last resort. Lifelong monitoring is necessary for all these patients.
CONCLUSION: The goal is to decrease the mass effect of the adenoma, to restore normal pituitary function, and to suppress hormone hypersecretion. Achievement of this goal necessitates the cooperation and interdisciplinary efforts of several medical specialties.

Entities:  

Mesh:

Year:  2008        PMID: 18996799     DOI: 10.4158/EP.14.6.757

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

1.  Multiplex immunoassays of peptide hormones extracted from formalin-fixed, paraffin-embedded tissue accurately subclassify pituitary adenomas.

Authors:  Frederick G Strathmann; Grace Borlee; Donald E Born; Luis F Gonzalez-Cuyar; Bertrand R Huber; Geoffrey S Baird
Journal:  Clin Chem       Date:  2011-12-28       Impact factor: 8.327

Review 2.  Atypical pituitary adenoma with orbital invasion: Case report and review of the literature.

Authors:  Mina M Naguib; Pia R Mendoza; Supharat Jariyakosol; Hans E Grossniklaus
Journal:  Surv Ophthalmol       Date:  2017-01-25       Impact factor: 6.048

3.  Acromegaly without imaging evidence of pituitary adenoma.

Authors:  Russell R Lonser; Bogdan A Kindzelski; Gautam U Mehta; John A Jane; Edward H Oldfield
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

4.  Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Authors:  I Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid A Siddiqui; Danilo Silva; Mayur Sharma; Hesham Radwan; Jonathan A Cohen; Robert F Dallapiazza; Christian Iorio-Morin; Amparo Wolf; John A Jane; Inga S Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Chih-Chun Wu; Christopher P Cifarelli; Tomas Chytka; Gene H Barnett; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurosurg       Date:  2017-10-27       Impact factor: 5.115

5.  Pituitary tumors.

Authors:  Nestoras Mathioudakis; Roberto Salvatori
Journal:  Curr Treat Options Neurol       Date:  2009-07       Impact factor: 3.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.